SOLIGENIX, INC. — fact timeline

Christopher Pullion changed role as Medical Director at SOLIGENIX, INC..

“Dr. Straube's responsibilities will be transitioned to Dr. Christopher Pullion, the Company's Medical Director.”

Richard C. Straube departed as Consulting Chief Medical Officer at SOLIGENIX, INC..

“Dr. Straube ceased serving as the Company's Consulting Chief Medical Officer.”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 10, 2026, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “SNGX,” and the Company is currently monitoring th”

SOLIGENIX, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“November 18, 2025, the Company received a letter from Nasdaq confirming that the Company had regained compliance with the Shareholders’ Equity Requirement and that the matter is now closed. ​”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“August 15, 2025, Soligenix, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, the Company reported stockholders’ equity of $1,828,951”

SOLIGENIX, INC.: Reduced quorum requirement for stockholder meetings from majority to one-third of voting power (effective 2025-03-25).

“The Amendment reduces the quorum required for the transaction of business at meetings of the Company’s stockholders from (i) the holders of a majority of the voting power of the shares of stock issued and outstanding and entitled to vote, to (ii) the holders of one-third (1/3) of the voting power of such shares, present in person or represented by proxy, unless otherwise required by applicable law or the Company’s certificate of incorporation.”

SOLIGENIX, INC. entered into Placement Agency Agreement with A.G.P./Alliance Global Partners valued at cash fee of six and one-half percent (6.5%) of the gross proceeds of the Offering (effective 2024-04-17).

“A.G.P./Alliance Global Partners acted as the sole placement agent (the “Placement Agent”) on a “reasonable best efforts” basis in connection with the Offering pursuant to a Placement Agency Agreement, dated April 17, 2024, by and between the Company and the Placement Agent (the “Placement Agency Agreement”).”

SOLIGENIX, INC. entered into Securities Purchase Agreement with certain investors valued at aggregate gross proceeds from the Offering are approximately $4.75 million (effective 2024-04-17).

“On April 17, 2024, Soligenix, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a public offering (the “Offering”) (i) 3,275,000 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 8,600,000 shares of the Company’s common stock and (iii) common warrants to purchase 11,875,000 shares of the Company’s common stock.”

SOLIGENIX, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“December 21, 2023, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule and is not eligible for a second 180 day period because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. In that regard, the Company’s Form 10-Q for the quarter ended September 30, 2023 reported stockholders’ equity of $4,221,155. As a result, the Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company”

SOLIGENIX, INC. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-12-15 meeting.

“Proposal Three Ratification of the Appointment of Independent Registered Public Accounting Firm: The proposal to ratify the appointment of Cherry Bekaert LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2023 was approved by votes as follows: For Against Abstain 4,439,358 188,624 887,512”

SOLIGENIX, INC. shareholders approved Non-binding advisory vote on executive compensation at the 2023-12-15 meeting.

“Proposal Two Non-binding advisory vote on executive compensation: The proposal to approve, by a non-binding advisory vote, the compensation of the Company’s named executive officers as disclosed in the Company’s 2023 proxy statement was approved, and the votes were as follows: For Against Abstain 2,315,274 707,529 889,790”

SOLIGENIX, INC. engaged Cherry Bekaert LLP as its auditor.

“on September 15, 2023, the Company to engaged Cherry Bekaert to serve as the Company’s independent registered public accounting firm to audit the Company’s financial statements for the fiscal year ending December 31, 2023”

SOLIGENIX, INC. dismissed EisnerAmper LLP as its auditor.

“the Audit Committee of the Board of Directors of the Company recommended and authorized the dismissal of EisnerAmper as the Company’s independent registered public accounting firm, and authorized the engagement of Cherry Bekaert LLP”

Timothy R. Coté resigned as member of the Board of Directors at SOLIGENIX, INC..

“On July 7, 2023, Timothy R. Coté resigned, for personal reasons, as a member of the Board of Directors of Soligenix, Inc.”

SOLIGENIX, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“June 23, 2023, Soligenix, Inc. (the “Company”) received a written notice (the “Bid Price Notice”) from the Listing Qualifications department (the “Nasdaq Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. The notification of noncompliance has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market under the symbol “SNGX,” and the Company is currently monitoring th”

SOLIGENIX, INC. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)).

“April 6, 2023, Nasdaq granted the Company’s request for an extension of the deadline by which it must regain compliance with the Shareholders’ Equity Requirement from March 31, 2023 to May 15, 2023. The Company is working diligently to satisfy, and intends to regain compliance with, the Shareholders’ Equity Requirement; however, there can be no assurance that the Company will be able to do so prior to the deadline established by Nasdaq, or at all, or that the Company’s common stock will remain listed on The Nasdaq Capital Market. ​ New Disclosure ​ As of the close of the market on May 9, 2023”

SOLIGENIX, INC. entered into Placement Agent Agreement with A.G.P./Alliance Global Partners valued at six percent (6%) of the gross proceeds of the Offering (effective 2023-05-05).

“A.G.P./Alliance Global Partners acted as the sole placement agent (the “Placement Agent”) on a “reasonable best efforts” basis in connection with the Offering pursuant to a Placement Agent Agreement, dated May 5, 2023, by and between the Company and the Placement Agent (the “Placement Agent Agreement”).”

SOLIGENIX, INC. entered into Securities Purchase Agreement with certain investors valued at approximately $8.5 million (effective 2023-05-05).

“On May 5, 2023, Soligenix, Inc., a Delaware corporation (the “Company”) entered into a Securities Purchase Agreement with certain investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors in a public offering (the “Offering”) (i) 2,301,500 shares of the Company’s common stock, (ii) pre-funded warrants to purchase 4,237,000 shares of the Company’s common stock and (iii) common warrants to purchase 6,538,500 shares of the Company’s common stock.”

Timothy R. Coté was appointed as director at SOLIGENIX, INC..

“On May 3, 2023, the Board of Directors (the “Board”) of Soligenix, Inc. (the “Company”) increased the size of the Board from five to six members and appointed Timothy R. Coté, MD, MPH as a director, with an initial term expiring at the Company’s 2023 Annual Meeting of Stockholders.”

SOLIGENIX, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“April 6, 2023, Nasdaq granted the Company’s request for an extension of the deadline by which it must regain compliance with the Shareholders’ Equity Requirement from March 31, 2023 to May 15, 2023. The Company is working diligently to satisfy, and intends to regain compliance with, the Shareholders’ Equity Requirement; however, there can be no assurance that the Company will be able to do so prior to the deadline established by Nasdaq, or at all, or that the Company’s common stock will remain listed on The Nasdaq Capital Market. ​ Safe Harbor for Forward-Looking Statements ​ Certain statement”

SOLIGENIX, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with”

SOLIGENIX, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with”

SOLIGENIX, INC.: Filed Certificate of Amendment to Second Amended and Restated Certificate of Incorporation to effect a 1-for-15 reverse stock split, effective 4:00 p.m. EST on February 9, 2023 (effective 2023-02-09).

“On February 8, 2023, Soligenix, Inc. (the “Company”) filed a Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of Delaware to effect a 1-for-15 reverse stock split of the shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding, effective as of 4:00 p.m. EST on February 9, 2023 (the “Reverse Stock Split”).”

SOLIGENIX, INC. shareholders approved To approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20 at the 2023-02-08 meeting.

“The Reverse Stock Split Proposal was approved by votes as follows: For Against Abstain 18,575,861,304 2,957,497,543 591,043,453”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

“November 16, 2022, Nasdaq notified us that we no longer complied with the continued listing requirement to maintain a minimum of $2,500,000 in stockholders’ equity nor did we meet the alternatives of market value of listed securities or net income from continuing operations. ​ The Company was unable to regain compliance with Minimum Bid Price Rule prior to the expiration of the second 180 calendar day period. On December 20, 2022, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule. The Notice indicated that”

SOLIGENIX, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 20, 2022, the Company received written notice (the “Notice”) from Nasdaq stating that the Company has not complied with the Minimum Bid Price Rule. The Notice indicated that the Company’s common stock would be suspended from trading on Nasdaq unless the Company requests a hearing before a hearings panel by December 27, 2022. The Company intends to timely request a hearing, which will stay any trading suspension of the Company’s common stock until completion of the Nasdaq hearing process and expiration of any additional extension period granted by the panel following the hearing. ​ The”

SOLIGENIX, INC. shareholders rejected proposal to approve an amendment to the Company’s Second Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 75,000,000 to 125,000,000 at the 2022-09-22 meeting.

“Despite support for Proposal 2 exceeding 80% of the votes cast on the proposal, Proposal 2 did not receive the affirmative vote of holders of more than 50% of the Company’s issued and outstanding shares of Common Stock and, therefore, was not approved. A large proportion of the stockholders holding shares through banks, brokers or other nominees could not be identified or were unresponsive to the Company’s outreach in urging them to vote their shares. The votes were as follows: For Against Abstain 19,250,158 4,741,417 409,816 There were no broker non-votes on this proposal.”

SOLIGENIX, INC. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“(the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, the Company reported stockholders’ equity of $1,032,002, which is below the Stockholders’ Equity Requirement for continued listing. Additionally, as of the date of this report, the Company does not meet either of the alternative Nasdaq”